Dermatol. praxi. 2015;9(3):99-103

Ustekinumab in treating psoriatic arthritis

MUDr.Hana Ciferská, Ph.D., MUDr.Jiří Štolfa
Revmatologický Ústav, Praha a Revmatologická klinika 1. LF UK Praha

Ustekinumab is a fully human IgG1κ monoclonal antibody that inhibits interleukin 12 and 23 functions by binding to their p40 subunit.

Ustekinumab is used in treating moderate and severe form of dermal psoriasis; however, a number of clinical studies have shown its effect

on extradermal manifestations, particularly on the musculoskeletal system. PSUMMIT-1 and -2 clinical studies in patients with psoriatic

arthritis have demonstrated good properties of ustekinumab for inducing a rapid therapeutic response with a good safety profile, and

allowed registration for this indication as well.

Keywords: ustekinumab, biological therapy, psoriasis, psoriatic arthritis

Published: October 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ciferská H, Štolfa J. Ustekinumab in treating psoriatic arthritis. Dermatol. praxi. 2015;9(3):99-103.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Gladman D. Current concepts in psoriatic arthritis. Curr Opin Rheumatol.2002; 14: 361-366. Go to original source... Go to PubMed...
    2. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973; 3: 55-78. Go to original source... Go to PubMed...
    3. McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology (Oxford) 2003; 42: 778. Go to original source... Go to PubMed...
    4. Mease PJ. Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis. Curr Opin Rheumatol. 2015; 27(2): 127-133. Go to original source... Go to PubMed...
    5. Tausend W, Downing C, Tyring S. Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab. J Cutan Med Surg. 2014; 18(3): 156-169. Go to original source...
    6. Benson JM, Peritt D, Scallon BJ, et al. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs. 2011; 3(6): 535-545. Go to original source... Go to PubMed...
    7. Stelara SPC, EMA dostupné online http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000958/WC500058513.pdf.
    8. Leonardi CL, Kimball AB, Papp KA, et al. PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).Lancet. 2008; 17; 371(9625): 1665-1674. Go to original source...
    9. Papp KA, Langley RG, Lebwohl M, et al. PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).Lancet. 2008; 17; 371(9625): 1675-1684. Go to original source...
    10. Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C, Fretzin S, Kunynetz R, Kavanaugh A. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009; 21; 373(9664): 633-640. Go to original source...
    11. McInnes I, Kavanaugh A, Gottlieb A, Puig L, Rahman P, Ritchlin C, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013; 382(9894): 780-789. Go to original source...
    12. Ritchlin C, Rahman P, Kavanaugh, et al. PSUMMIT 2 Study Group. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014; 73(6): 990-999. Go to original source... Go to PubMed...
    13. Kavanaugh A, Ritchlin C, Rahman P, et al. PSUMMIT-1 and 2 Study Groups. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibitsradiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis. 2014; 73(6): 1000-1006. Go to original source...
    14. Griffiths CE, Strober BE, van de Kerkhof P et al ACCEPT Study Group. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010; 362 (2): 118-128. Go to original source...
    15. Gottlieb A, Narang K. Ustekinumab in the treatment of psoriatic arthritis: latest findings and clinical potential. Ther Adv Musculoskelet Dis. 2013; 5(5): 277-285. Go to original source...
    16. Štolfa J, Vencovský J, Pavelka K. Doporučené postupy České revmatologické společnosti pro léčbu psoriatické artritidy Čes. Revmatol., 20, 2012; No. 1, p. 13-18.
    17. Kavanaugh A, et al. Maintenance of clinical efficacy and radiographic benefit through 2 years of ustekinumab therapy in patients with active psoriatic arthritis: Results from the PSUMMIT 1 trial. Arthritis Care Res (Hoboken), 19. 6. 2015, doi: 10.1002/acr.22645. Go to original source...
    18. Štolfa J. Co můžeme udělat pro pacienta s psoriatickou artritidou, když selžou inhibitory TNF??, Acta Medicinae 2015; 6: 70-75.

    Return to the content


    Dermatology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.